Summary & Overview
HCPCS G9062: Oncology Management Differing from Guidelines
HCPCS Level II code G9062 identifies oncology care in which management intentionally departs from standard practice guidelines for reasons not listed elsewhere, used specifically within Medicare-approved demonstration projects. Nationally, this code matters because it documents guideline deviations in cancer care that may inform policy, quality measurement, and demonstration evaluations focused on complex clinical decision-making.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the clinical and service contexts where it applies, and which major payers are relevant to reimbursement and policy discussions. The publication outlines where G9062 is applicable (oncology clinics and outpatient cancer centers participating in demonstration projects) and highlights implications for coding consistency, documentation expectations, and demonstration reporting.
The report provides benchmarks and policy context when available, notes gaps where data are not provided, and summarizes operational considerations for providers and administrators who encounter this code in demonstration settings.
Billing Code Overview
HCPCS Level II code G9062 denotes oncology practice guidelines where management differs from guidelines for other reasons not listed, intended for use in a Medicare-approved demonstration project. The code captures instances in which oncology care deviates from standard guideline-directed management for reasons not otherwise specified in existing codes.
Service type: Oncology guideline-based management with documented deviations
Typical site of service: Oncology clinic or outpatient cancer center participating in a Medicare demonstration project
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of advanced non-small cell lung cancer is enrolled in a Medicare-approved oncology demonstration project assessing alternative guideline-driven management strategies. The treating oncology practice documents that standard guideline algorithms are intentionally modified due to study protocol criteria and patient-specific factors (comorbid cardiac disease, prior toxicities, and patient preference). The clinical workflow begins with an interdisciplinary tumor board review documenting the deviation from published guideline pathways. The oncologist documents the rationale and plan in the medical record, orders alternative systemic therapy or altered surveillance frequency, obtains informed consent for the demonstration protocol, coordinates with pharmacy for regimen adjustments, and schedules follow-up visits and imaging. Billing for the demonstration-specific guideline deviation is reported using G9062 alongside usual evaluation and management and procedural codes as appropriate. Relevant modifiers (for example, financial compliance or bilateral procedures) are appended per normal billing rules. Typical sites of service include hospital outpatient departments, physician offices, and academic cancer centers participating in the Medicare demonstration project.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No information provided (placeholder) | Rarely used; retained for vendor/system completeness when no modifier applies. |